AR112482A1 - Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry - Google Patents
Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabryInfo
- Publication number
- AR112482A1 AR112482A1 ARP180102438A AR112482A1 AR 112482 A1 AR112482 A1 AR 112482A1 AR P180102438 A ARP180102438 A AR P180102438A AR 112482 A1 AR112482 A1 AR 112482A1
- Authority
- AR
- Argentina
- Prior art keywords
- cardiac function
- fabry
- disease
- patients
- methods
- Prior art date
Links
- 230000004217 heart function Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000024720 Fabry Disease Diseases 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- LXBIFEVIBLOUGU-DPYQTVNSSA-N migalastat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O LXBIFEVIBLOUGU-DPYQTVNSSA-N 0.000 abstract 1
- 229950007469 migalastat Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Reivindicación 1: Un método para mejorar la función cardiaca en un paciente que tiene enfermedad de Fabry, en donde el método comprende administrar al paciente una formulación que comprende una cantidad eficaz de migalastat o una sal del mismo cada dos días para mejorar la función cardiaca del paciente, en donde la cantidad eficaz es de entre aproximadamente 100 mg y aproximadamente 150 mg equivalentes de base libre (FBE).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762550984P | 2017-08-28 | 2017-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112482A1 true AR112482A1 (es) | 2019-10-30 |
Family
ID=63528948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180102438 AR112482A1 (es) | 2017-08-28 | 2018-08-28 | Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20200222377A1 (es) |
| EP (2) | EP4176877A1 (es) |
| JP (2) | JP2020531550A (es) |
| KR (1) | KR20200044908A (es) |
| CN (1) | CN111770753A (es) |
| AR (1) | AR112482A1 (es) |
| AU (1) | AU2018326364A1 (es) |
| BR (1) | BR112020003974A2 (es) |
| CA (1) | CA3074450A1 (es) |
| CL (1) | CL2020000491A1 (es) |
| DK (1) | DK3675853T3 (es) |
| EA (1) | EA202090564A1 (es) |
| ES (1) | ES2931054T3 (es) |
| HR (1) | HRP20221366T1 (es) |
| HU (1) | HUE060287T2 (es) |
| IL (2) | IL310648A (es) |
| LT (1) | LT3675853T (es) |
| MX (2) | MX2020002229A (es) |
| PL (1) | PL3675853T3 (es) |
| PT (1) | PT3675853T (es) |
| RS (1) | RS63742B1 (es) |
| SG (1) | SG11202001707PA (es) |
| TW (1) | TW201919619A (es) |
| WO (1) | WO2019046244A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2652553C (en) | 2006-05-16 | 2020-08-18 | Amicus Therapeutics, Inc. | Use of 1-deoxygalactonojirimycin or a salt thereof in the treatment of fabry disease |
| ES2541933T3 (es) | 2008-02-12 | 2015-07-28 | Amicus Therapeutics, Inc. | Método para predecir la respuesta al tratamiento farmacológico con chaperona de enfermedades |
| US10251873B2 (en) | 2017-05-30 | 2019-04-09 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| KR20200128676A (ko) | 2018-02-06 | 2020-11-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도 |
| AU2020327019A1 (en) | 2019-08-07 | 2022-03-03 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US20100113517A1 (en) | 2007-03-30 | 2010-05-06 | Amicus Therapeutics, Inc. | Method for the treatment of fabry disease using pharmacological chaperones |
| US9999618B2 (en) * | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| ES2541933T3 (es) | 2008-02-12 | 2015-07-28 | Amicus Therapeutics, Inc. | Método para predecir la respuesta al tratamiento farmacológico con chaperona de enfermedades |
-
2018
- 2018-08-28 HU HUE18766482A patent/HUE060287T2/hu unknown
- 2018-08-28 US US16/642,620 patent/US20200222377A1/en active Pending
- 2018-08-28 EP EP22194251.9A patent/EP4176877A1/en active Pending
- 2018-08-28 EA EA202090564A patent/EA202090564A1/ru unknown
- 2018-08-28 SG SG11202001707PA patent/SG11202001707PA/en unknown
- 2018-08-28 CN CN201880056413.8A patent/CN111770753A/zh active Pending
- 2018-08-28 CA CA3074450A patent/CA3074450A1/en active Pending
- 2018-08-28 TW TW107129901A patent/TW201919619A/zh unknown
- 2018-08-28 DK DK18766482.6T patent/DK3675853T3/da active
- 2018-08-28 IL IL310648A patent/IL310648A/en unknown
- 2018-08-28 PL PL18766482.6T patent/PL3675853T3/pl unknown
- 2018-08-28 LT LTEPPCT/US2018/048257T patent/LT3675853T/lt unknown
- 2018-08-28 RS RS20221061A patent/RS63742B1/sr unknown
- 2018-08-28 AR ARP180102438 patent/AR112482A1/es unknown
- 2018-08-28 AU AU2018326364A patent/AU2018326364A1/en active Pending
- 2018-08-28 MX MX2020002229A patent/MX2020002229A/es unknown
- 2018-08-28 JP JP2020511971A patent/JP2020531550A/ja active Pending
- 2018-08-28 WO PCT/US2018/048257 patent/WO2019046244A1/en unknown
- 2018-08-28 ES ES18766482T patent/ES2931054T3/es active Active
- 2018-08-28 HR HRP20221366TT patent/HRP20221366T1/hr unknown
- 2018-08-28 PT PT187664826T patent/PT3675853T/pt unknown
- 2018-08-28 EP EP18766482.6A patent/EP3675853B1/en active Active
- 2018-08-28 BR BR112020003974-8A patent/BR112020003974A2/pt unknown
- 2018-08-28 KR KR1020207008736A patent/KR20200044908A/ko not_active Application Discontinuation
- 2018-08-28 IL IL272893A patent/IL272893B1/en unknown
-
2020
- 2020-02-27 MX MX2023005628A patent/MX2023005628A/es unknown
- 2020-02-28 CL CL2020000491A patent/CL2020000491A1/es unknown
-
2022
- 2022-12-20 JP JP2022203783A patent/JP2023051998A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA202090564A1 (ru) | 2020-06-15 |
| JP2020531550A (ja) | 2020-11-05 |
| CN111770753A (zh) | 2020-10-13 |
| EP3675853A1 (en) | 2020-07-08 |
| US20200222377A1 (en) | 2020-07-16 |
| MX2023005628A (es) | 2023-05-24 |
| AU2018326364A1 (en) | 2020-04-09 |
| DK3675853T3 (da) | 2022-11-28 |
| ES2931054T3 (es) | 2022-12-23 |
| EP4176877A1 (en) | 2023-05-10 |
| KR20200044908A (ko) | 2020-04-29 |
| LT3675853T (lt) | 2022-12-12 |
| PT3675853T (pt) | 2022-11-28 |
| TW201919619A (zh) | 2019-06-01 |
| CL2020000491A1 (es) | 2020-09-11 |
| EP3675853B1 (en) | 2022-09-07 |
| RS63742B1 (sr) | 2022-12-30 |
| HUE060287T2 (hu) | 2023-02-28 |
| IL272893B1 (en) | 2024-03-01 |
| HRP20221366T1 (hr) | 2023-01-06 |
| SG11202001707PA (en) | 2020-03-30 |
| IL272893A (en) | 2020-04-30 |
| IL310648A (en) | 2024-04-01 |
| JP2023051998A (ja) | 2023-04-11 |
| PL3675853T3 (pl) | 2022-12-27 |
| CA3074450A1 (en) | 2019-03-07 |
| MX2020002229A (es) | 2020-07-20 |
| WO2019046244A1 (en) | 2019-03-07 |
| BR112020003974A2 (pt) | 2020-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112482A1 (es) | Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| JOP20200156A1 (ar) | إيسكيتامين لعلاج الاكتئاب | |
| CL2019003496A1 (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| BR112018069251A2 (pt) | métodos de intervenção precoce para prevenir ou melhorar a toxicidade | |
| AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
| AR095338A1 (es) | Método de tratamiento no tóxico para la abstinencia de drogas | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| CO2020013600A2 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| BR112013010829A2 (pt) | composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| BR112019023981A2 (pt) | injeção de octreotida | |
| CO2022005113A2 (es) | Métodos de tratamiento para modificar la hemodinámica | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| AR109102A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| PA8806001A1 (es) | Nuevo uso medico de las sales de propionato de 3-(2,2,2-trimetilhidrazinio) en el tratamiento de la enfermedad cardíaca isquémica | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| AR111971A1 (es) | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal | |
| PL425351A1 (pl) | Kompozycja zawierająca peptyd IM, zestaw oraz zastosowanie do pobudzania regeneracji tkanki złożonej lub leczenia ran |